Also, last point here.
It's clear you're intentionally distorting my previous point, about difficulties prescribing regulated medications off label in a hospital setting.
The fact you can't actually address the points I make, yet feel it's so necessary to misconstrue them makes me there's more to this than just ignorance (but maybe I'm just being generous).
People browsing through these forums, take everything with a grain of salt. Medicine is complex. And many around here think they understand much more than they do.
Small cap biotech is a risky field. Stem cells are an extremely risky field (as I've said before, most stem cell companies fail at the phase three stage: that is currently where MSB is stuck).
Combine a complex field that most don't understand with a very risky investment and a bunch of LTHers who are likely staring at a big red screen, of course you're going to get some fervent defenders trying to drown out anyone who comes here with a critical eye.
Just beware, DYOR, and if the first you're hearing about MSCs is here and not in a lecture theatre maybe think twice about investing in this tech.
Cell Therapy News/Articles, page-13490
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.31 |
Change
-0.010(0.76%) |
Mkt cap ! $1.495B | |||
| Open | High | Low | Value | Volume |
| $1.31 | $1.33 | $1.28 | $1.819M | 1.396M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 29972 | $1.31 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.31 | 2008 | 1 |
View Market Depth
| Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |